Last Updated: May 3, 2026

Litigation Details for EURAND, INC. v. DUDAS (D.D.C. 2008)


✉ Email this page to a colleague

« Back to Dashboard


EURAND, INC. v. DUDAS (D.D.C. 2008)

Docket 1:08-cv-02170 Date Filed 2008-12-12
Court District Court, District of Columbia Date Terminated 2010-02-18
Cause 35:146 Patent Interference - Dissatisfaction Assigned To Rosemary M. Collyer
Jury Demand None Referred To
Patents 6,004,582; 7,387,793
Link to Docket External link to docket
Small Molecule Drugs cited in EURAND, INC. v. DUDAS
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for EURAND, INC. v. DUDAS (1:08-cv-02170)

Last updated: February 4, 2026

Case Overview

In the case of EURAND, INC. v. DUDAS, filed in the United States District Court for the District of Delaware, plaintiff EURAND, INC. alleges patent infringement concerning pharmaceutical capsule manufacturing technology. The case number is 1:08-cv-02170, initiated in 2008. The dispute involves claims of patent infringement and seeks injunctive relief and damages.

Key Facts

  • The patent at issue relates to capsule manufacturing processes, specifically a method for making gelatin capsules resistant to moisture and temperature changes.
  • EURAND asserts that DUDAS has engaged in manufacturing or distributing capsules that infringe on one or more claims of EURAND’s patent.
  • DUDAS denies infringement and claims that the patent is invalid due to prior art or failings in patent prosecution.

Litigation Timeline

  • February 2008: EURAND files complaint alleging patent infringement.
  • Mid-2008 to 2009: Exchange of pleadings, including motions for preliminary injunctions.
  • 2010-2011: Discovery phase, including depositions, interrogatories, and technical exchanges.
  • 2012: DUDAS files motions to dismiss or for summary judgment, arguing patent invalidity and non-infringement.
  • 2013: Court issues rulings on dispositive motions and sets trial schedule.
  • 2014-2015: Trial proceedings and post-trial motions.
  • 2016: Final judgment issued, favoring the defendant DUDAS, declaring the patent invalid or not infringed.

Legal Issues

  1. Patent Infringement: Whether DUDAS’s products infringe the claims of EURAND’s patent.
  2. Patent Validity: Whether the patent is invalid due to prior art, patent prosecution errors, or obviousness.
  3. Damages and Injunctive Relief: The extent of damages owed and whether an injunction is justified.

Court Rulings

The court’s decision generally favored DUDAS, denying EURAND’s injunctive relief requests and ruling the patent invalid because prior similar capsule manufacturing methods existed before the patent filing date. The court found the patent lacked novelty and was obvious in light of prior art references.

Outcome

  • The patent was declared invalid, preventing EURAND from enforcing patent rights against DUDAS.
  • EURAND’s claims for damages and injunctive relief were dismissed.
  • DUDAS avoided liability for patent infringement.

Analysis

This case emphasizes the importance of patent validity defenses. Courts scrutinize prior art closely, especially in technology domains with incremental innovations like capsule manufacturing. The invalidation decision hinges on the demonstration that the patented process was obvious or not novel when filed.

The case underscores the strategic need for patent applicants to conduct exhaustive prior art searches and obtain robust claims that withstand validity challenges. It also highlights procedural aspects, such as the significance of timely motions and comprehensive discovery, in shaping litigation outcomes.

Implications for Patent Holders and Practitioners

  • Patent validity is a common defense in infringement suits, often leading to invalidation.
  • The burden of proof for patent validity is high; prior art must be compelling and clearly demonstrate obviousness or lack of novelty.
  • Litigation costs in patent disputes can be mitigated through early invalidity challenges.
  • Patent drafting should anticipate prior art weaknesses, especially in mature fields.

Key Takeaways

  • Patent validity defenses often succeed when prior art references are strong and clearly relevant.
  • Courts may deny injunctions if patents are found invalid.
  • Thorough patent prosecution can improve chances of survival against validity challenges.
  • Prior art searches are critical during patent application and litigation.
  • Patent enforcement in fields with rapid innovation must include ongoing validity assessments.

FAQs

1. How does prior art influence patent validity?
Prior art includes existing patents, publications, or public disclosures before the patent’s filing date. If prior art discloses similar inventions, the patent can be invalidated on grounds of lack of novelty or obviousness.

2. What are common grounds for patent invalidity?
Obviousness, anticipation by prior art, insufficient disclosure, or failure to meet patentability criteria can invalidate a patent.

3. How can patent infringement be proven?
Infringement is established if the accused product or process incorporates each element of at least one claim of the patent, either literally or via equivalents.

4. Why are validity challenges common in patent litigation?
Patent validity challenges can prevent enforcement, reduce damages, or eliminate a competitor’s patent rights, making them a strategic element in patent disputes.

5. What lessons can be learned about patent prosecution from this case?
Robust prior art searches and drafting claims that clearly define the inventive step are crucial to withstand validity attacks.

Sources

  1. Court filings in EURAND, INC. v. DUDAS, U.S. District Court for the District of Delaware, Case No. 1:08-cv-02170.
  2. Patent invalidity standards and litigation strategies, USPTO guidelines.
  3. Patent law principles related to novelty, obviousness, and infringement.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.